- $365.45m
- $1.64bn
- $1.08bn
Brief: Embecta Announces FDA 510(K) Submission For Insulin Patch Pump
Brief: No Embecta-Made Syringes Impacted By FDA Safety Communication
U.S. STOCKS ON THE MOVE-Baidu, Lowe's Companies, Best Buy
Embecta hits over two-month high as Q4 profit, revenue beat estimates
Embecta Corp reports results for the quarter ended in September - Earnings Summary
Brief: Embecta Reports Fiscal 2023 Fourth Quarter Results
Brief: Embecta Q4 Revenue USD 281.9 Million
Embecta Corp reports results for the quarter ended in June - Earnings Summary
Brief: Embecta Q3 Revenue USD 286.1 Million
Embecta Corp expected to post earnings of 46 cents a share - Earnings Preview
Embecta Corp reports results for the quarter ended in March - Earnings Summary
Brief: Embecta And Tidepool Partner To Develop Automated Insulin Delivery System For People With Type 2 Diabetes
Brief: Embecta Corp. Reports Q2 Fiscal 2023 Financial Results
Brief: Embecta Q2 revenue USD 277.1 million
Embecta Corp expected to post earnings of 49 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Packaged food makers, energy firms, Thomson Reuters
Embecta Corp rises on beating earnings estimates
Embecta Corp reports results for the quarter ended in December - Earnings Summary
Brief: Embecta Corp. Reports First Quarter Fiscal 2023 Financial Results